Genprex, Inc. Segments Disclosure
Note 8 – Segment Reporting
Operating segments are defined as components of an entity for which separate discrete financial information is made available and that is regularly evaluated by the CODM in making decisions regarding resource allocation and assessing performance. The Company manages its operations as a single segment (the “Segment”) for the purposes of assessing performance and making operating decisions. The CODM of the Segment is the Company’s Chief Executive Officer. The Segment is focused on pioneering the discovery and development of gene therapies for use in patient populations with unmet medical needs. The accounting policies for the Segment are the same as those described in Note 2, Summary of Significant Accounting Policies. The CODM assesses the performance of the Segment and decides how to allocate resources based on net loss that is reported on the statements of operations and comprehensive loss. Further, the following represents information about segment loss and significant segment expenses:
| Year Ended | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenues | $ | — | $ | — | ||||
| Less: | ||||||||
| Clinical and regulatory | 6,785,848 | 7,809,750 | ||||||
| Manufacturing | 1,258,765 | 1,658,373 | ||||||
| Research | 1,281,852 | 483,927 | ||||||
| General and administrative support | 5,872,327 | 7,877,622 | ||||||
| Non-cash expenses(1) | 316,827 | 3,344,495 | ||||||
| Other income | 26,900 | 63,574 | ||||||
| Plus: | ||||||||
| Other financing costs | (739,935 | ) | — | |||||
| Realized and unrealized loss | (299 | ) | (570 | ) | ||||
| Segment and net loss | $ | 16,228,953 | $ | 21,111,163 | ||||
(1) Inclusive of $0.3 million and $3.3 million of stock-based compensation expense for the years ended December 31, 2025 and 2024, respectively, and $0 and $6,693 of depreciation and amortization expense for the years ended December 31, 2025 and 2024, respectively.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Apr 1, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.